Manipulation of receptor oligomerization as a strategy to inhibit signaling by TNF superfamily members

Science Signaling

Volumn 7, Issue 339, 2014, Pages

  Warren, Julia T ^a   Nelson, Christopher A ^a   Decker, Corinne E ^a   Zou, Wei ^a   Fremont, Daved H ^a   Teitelbaum, Steven L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11A PROTEIN, MOUSE; TNFRSF11B PROTEIN, MOUSE; TNFSF11 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; GENE MUTATION; IN VITRO STUDY; MOUSE; NONHUMAN; OLIGOMERIZATION; OSTEOCLASTOGENESIS; OSTEOLYSIS; PROTEIN ENGINEERING; RECEPTOR BINDING; AMINO ACID SUBSTITUTION; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETICS; HUMAN; METABOLISM; MISSENSE MUTATION; OSTEOCLAST; PROTEIN MULTIMERIZATION; SIGNAL TRANSDUCTION;

AMINO ACID SUBSTITUTION; ANIMALS; BONE RESORPTION; HUMANS; MICE; MUTATION, MISSENSE; OSTEOCLASTS; OSTEOPROTEGERIN; PROTEIN MULTIMERIZATION; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION;

EID: 84906824147     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2004948     Document Type: Article

References (38)

1. M. Croft, W. Duan, H. Choi, S. Y. Eun, S. Madireddi, A. Mehta, TNF superfamily in inflammatory disease: Translating basic insights. Trends Immunol. 33, 144-152 (2012).
2. D. S. Vinay, B. S. Kwon, The tumour necrosis factor/TNF receptor superfamily: Therapeutic targets in autoimmune diseases. Clin. Exp. Immunol. 164, 145-157 (2011).
3. M. G. Tansey, D. E. Szymkowski, The TNF superfamily in 2009: New pathways, new indications, and new drugs. Drug Discov. Today 14, 1082-1088 (2009).
4. Y. Y. Kong, H. Yoshida, I. Sarosi, H. L. Tan, E. Timms, C. Capparelli, S. Morony, A. J. Oliveira-dos-Santos, G. Van, A. Itie,W. Khoo, A. Wakeham, C. R. Dunstan, D. L. Lacey, T. W. Mak, W. J. Boyle, J. M. Penninger, OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315-323 (1999).
5. N. Kim, P. R. Odgren, D. K. Kim, S. C. Marks Jr., Y. Choi, Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc. Natl. Acad. Sci. U.S.A. 97, 10905-10910 (2000).
6. T. L. Burgess, Y. Qian, S. Kaufman, B. D. Ring, G. Van, C. Capparelli, M. Kelley, H. Hsu, W. J. Boyle, C. R. Dunstan, S. Hu, D. L. Lacey, The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J. Cell Biol. 145, 527-538 (1999).
7. D. L. Lacey, E. Timms, H. L. Tan, M. J. Kelley, C. R. Dunstan, T. Burgess, R. Elliott, A. Colombero, G. Elliott, S. Scully, H. Hsu, J. Sullivan, N. Hawkins, E. Davy, C. Capparelli, A. Eli, Y. X. Qian, S. Kaufman, I. Sarosi, V. Shalhoub, G. Senaldi, J. Guo, J. Delaney, W. J. Boyle, Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176 (1998).
8. J. Lam, C. A. Nelson, F. P. Ross, S. L. Teitelbaum, D. H. Fremont, Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. J. Clin. Invest. 108, 971-979 (2001).
9. C. A. Nelson, J. T. Warren, M. W. Wang, S. L. Teitelbaum, D. H. Fremont, RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor. Structure 20, 1971-1982 (2012).
10. C. Liu, T. S. Walter, P. Huang, S. Zhang, X. Zhu, Y. Wu, L. R. Wedderburn, P. Tang, R. J. Owens, D. I. Stuart, J. Ren, B. Gao, Structural and functional insights of RANKL-RANK interaction and signaling. J. Immunol. 184, 6910-6919 (2010).
11. H. M. Ta, G. T. Nguyen, H. M. Jin, J. Choi, H. Park, N. Kim, H. Y. Hwang, K. K. Kim, Structure-based development of a receptor activator of nuclear factor-κB ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis. Proc. Natl. Acad. Sci. U.S.A. 107, 20281-20286 (2010).
12. D. L. Lacey, W. J. Boyle, W. S. Simonet, P. J. Kostenuik, W. C. Dougall, J. K. Sullivan, J. San Martin, R. Dansey, Bench to bedside: Elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat. Rev. Drug Discov. 11, 401-419 (2012).
13. A. Krippner-Heidenreich, I.Grunwald, G. Zimmermann, M. Kühnle, J. Gerspach, T. Sterns, S. D. Shnyder, J. H. Gill, D. N. Männel, K. Pfizenmaier, P. Scheurich, Single-chain TNF, a TNF derivative with enhanced stability and antitumoral activity. J. Immunol. 180, 8176- 8183 (2008).
14. V. Boschert, A. Krippner-Heidenreich, M. Branschädel, J. Tepperink, A. Aird, P. Scheurich, Single chain TNF derivatives with individually mutated receptor binding sites reveal differential stoichiometry of ligand receptor complex formation for TNFR1 and TNFR2. Cell. Signal. 22, 1088-1096 (2010).
15. B. Schneider, S. Münkel, A. Krippner-Heidenreich, I. Grunwald, W. S. Wels, H. Wajant, K. Pfizenmaier, J. Gerspach, Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins. Cell Death Dis. 1, e68 (2010).
16. D. Spitzer, J. E. McDunn, S. Plambeck-Suess, P. S. Goedegebuure, R. S. Hotchkiss, W. G. Hawkins, A genetically encoded multifunctional TRAIL trimer facilitates cell-specific targeting and tumor cell killing. Mol. Cancer Ther. 9, 2142-2151 (2010).
17. S. A. Gai, K. D. Wittrup, Yeast surface display for protein engineering and characterization. Curr. Opin. Struct. Biol. 17, 467-473 (2007).
18. H. Yasuda, N. Shima, N. Nakagawa, S. I. Mochizuki, K. Yano, N. Fujise, Y. Sato, M. Goto, K. Yamaguchi, M. Kuriyama, T. Kanno, A. Murakami, E. Tsuda, T. Morinaga, K. Higashio, Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139, 1329-1337 (1998).
19. W. S. Simonet, D. L. Lacey, C. R. Dunstan, M. Kelley, M. S. Chang, R. Lüthy, H. Q. Nguyen, S. Wooden, L. Bennett, T. Boone, G. Shimamoto, M. DeRose, R. Elliott, A. Colombero, H. L. Tan, G. Trail, J. Sullivan, E. Davy, N. Bucay, L. Renshaw-Gegg, T. M. Hughes, D. Hill, W. Pattison, P. Campbell, S. Sander, G. Van, J. Tarpley, P. Derby, R. Lee, W. J. Boyle, Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89, 309-319 (1997).
20. L. A. Schneeweis, D. Willard, M. E. Milla, Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-κB ligand. J. Biol. Chem. 280, 41155-41164 (2005).
21. T. Hehlgans, K. Pfeffer, The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: Players, rules and the games. Immunology 115, 1-20 (2005).
22. J. J. Peschon, D. S. Torrance, K. L. Stocking, M. B. Glaccum, C. Otten, C. R. Willis, K. Charrier, P. J. Morrissey, C. B. Ware, K. M. Mohler, TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J. Immunol. 160, 943-952 (1998).
23. D. Mewar, A. G. Wilson, Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors. Br. J. Pharmacol. 162, 785-791 (2011).
24. F. Van Hauwermeiren, R. E. Vandenbroucke, C. Libert, Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1. Cytokine Growth Factor Rev. 22, 311-319 (2011).
25. E. C. Keystone, Does anti-tumor necrosis factor-a therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: A review of longterm data. J. Rheumatol. 38, 1552-1562 (2011).
26. T. Bongartz, A. J. Sutton, M. J. Sweeting, I. Buchan, E. L. Matteson, V. Montori, Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295, 2275-2285 (2006).
27. S. Blüml, C. Scheinecker, J. S. Smolen, K. Redlich, Targeting TNF receptors in rheumatoid arthritis. Int. Immunol. 24, 275-281 (2012).
28. G. Kollias, D. Kontoyiannis, Role of TNF/TNFR in autoimmunity: Specific TNF receptor blockade may be advantageous to anti-TNF treatments. Cytokine Growth Factor Rev. 13, 315-321 (2002).
29. S. G. Hymowitz, A. M. de Vos, Structures of TNF receptors and their interactions with ligands. In Death Receptors in Cancer Therapy,W. El-Deiry, Ed. (Humana Press, Totowa, NJ, 2005), pp. 65-81.
30. Y. Mukai, T. Nakamura, M. Yoshikawa, Y. Yoshioka, S. Tsunoda, S. Nakagawa, Y. Yamagata, Y. Tsutsumi, Solution of the structure of the TNF-TNFR2 complex. Sci. Signal. 3, ra83 (2010).
31. P.M. Steed,M. G. Tansey, J. Zalevsky, E. A. Zhukovsky, J.R.Desjarlais, D. E. Szymkowski, C. Abbott, D. Carmichael, C. Chan, L. Cherry, P. Cheung, A. J. Chirino, H. H. Chung, S. K. Doberstein, A. Eivazi, A. V. Filikov, S. X. Gao, R. S. Hubert, M. Hwang, L. Hyun, S. Kashi, A. Kim, E. Kim, J. Kung, S. P. Martinez, U. S.Muchhal, D. H. Nguyen, C.O'Brien, D.O'Keefe, K. Singer,O. Vafa, J. Vielmetter, S. C. Yoder, B. I. Dahiyat, Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science 301, 1895-1898 (2003).
32. F. Mancia, S. D. Patel, M.W. Rajala, P. E. Scherer, A. Nemes, I. Schieren,W. A. Hendrickson, L. Shapiro, Optimization of protein production in mammalian cells with a coexpressed fluorescent marker. Structure 12, 1355-1360 (2004).
33. A. R. Aricescu,W. Lu, E. Y. Jones, A time- and cost-efficient system for high-level protein production in mammalian cells. Acta Crystallogr. D Biol. Crystallogr. 62, 1243-1250 (2006).
34. T. Izawa, W. Zou, J. C. Chappel, J. W. Ashley, X. Feng, S. L. Teitelbaum, c-Src links a RANK/αvβ3 integrin complex to the osteoclast cytoskeleton. Mol. Cell. Biol. 32, 2943-2953 (2012).
35. S. Takeshita, K. Kaji, A. Kudo, Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. J. Bone Miner. Res. 15, 1477-1488 (2000).
36. R. D. Gietz, R. H. Schiestl, Large-scale high-efficiency yeast transformation using the LiAc/SS carrier DNA/PEG method. Nat. Protoc. 2, 38-41 (2007).
37. C. J. DeSelm, Y. Takahata, J. Warren, J. C. Chappel, T. Khan, X. Li, C. Liu, Y. Choi, Y. F. Kim, W. Zou, S. L. Teitelbaum, IL-17 mediates estrogen-deficient osteoporosis in an Act1-dependent manner. J. Cell. Biochem. 113, 2895-2902 (2012).
38. Y. Tomimori, K. Mori, M. Koide, Y. Nakamichi, T. Ninomiya, N. Udagawa, H. Yasuda, Evaluation of pharmaceuticals with a novel 50-hour animal model of bone loss. J. Bone Miner. Res. 24, 1194-1205 (2009).